[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ankylosing-spondylitis-as--radiographic-axial-spa-r-axspa\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ankylosing-spondylitis-as--radiographic-axial-spa-r-axspa":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100638927","phase-4-effectiveness-and-safety-of-acemetacin-in-active-axial-spondyloarthritis-a-real-world-study-100638927",false,"NCT07582146","Effectiveness and Safety of Acemetacin in Active Axial Spondyloarthritis: A Real-world Study","Effectiveness and Safety of Acemetacin in Patients With Active Axial Spondyloarthritis: A Prospective, Multicenter, Observational Real-World Study","ARISE","Inclusion Criteria:\n\n* Subjects who fully understand the purpose and procedures of the trial and voluntarily sign the Informed Consent Form (ICF);\n* Subjects aged 18-65 years (inclusive), regardless of gender;\n* Meet the 2025 ASAS-SPARTAN Revised Classification Criteria for Axial Spondyloarthritis;\n* ASDAS score \\> 2.1.\n\nExclusion Criteria:\n\n* Subjects with known allergy to acemetacin, other NSAIDs, or any excipients;\n* Subjects with active gastrointestinal ulcer\u002Fbleeding, or a history of recurrent ulcer\u002Fbleeding;\n* Subjects with severe cardiac or renal dysfunction, or hepatic dysfunction;\n* Subjects with ulcerative colitis or Crohn's disease;\n* Subjects who received systemic glucocorticoids or intra-articular glucocorticoid injections within 3 months prior to the study start;\n* Subjects who received targeted therapy within 3 months prior to the study start;\n* Any other condition that, in the investigator's opinion, makes the subject unsuitable for participation in this study.","ALL","18 Years","65 Years",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The goal of this observational study is to evaluate the effectiveness and safety of acemetacin in adults (18-65 years) with active axial spondyloarthritis (axSpA) who meet the 2025 ASAS-SPARTAN revised classification criteria and have an ASDAS score greater than 2.1.\n\nThe main questions this study aims to answer are:\n\n* Does acemetacin reduce overall pain assessed by visual analog scale (VAS) after 4 weeks of treatment?\n* What proportion of patients achieve clinical remission (ASDAS ≤1.3) or low disease activity (1.3\\\u003CASDAS≤2.1) at week 4?\n* What medical problems (side effects) occur during acemetacin treatment, with particular attention to gastrointestinal and cardiovascular events?\n\nParticipants will:\n\n* Undergo screening assessments including blood tests, imaging of the sacroiliac joints (MRI, CT, X-ray), and physical examination within 7 days before starting treatment\n* Take acemetacin 90 mg by mouth once daily for 4 weeks\n* Complete a phone follow-up at week 2 and an in-clinic visit at week 4\n* Have pain scores, disease activity measures (ASDAS, BASDAI, BASFI, ASAS HI, BASMI), and laboratory tests (CRP, ESR) recorded at each visit\n* Be monitored for adverse events throughout the treatment period",[28,29,30],"Axial Spondyloarthritis","Axial Spondyloarthritis, Non-Radiographic","Ankylosing Spondylitis (AS) \u002F Radiographic Axial SpA (r-axSpA)",[32,28,33,34],"Acemetacin","NSAIDs","Real-World Study","NOT_YET_RECRUITING","2026-05-06",{"date":38,"type":39},"2026-05-12","ACTUAL",{"date":41,"type":22},"2026-04",{"date":43,"type":22},"2026-12",{"name":45,"class":46},"Chinese PLA General Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100513084","chinese-spondyloarthritis-inception-cohort-cespic-100513084","NCT05960864","Chinese Spondyloarthritis Inception Cohort (CESPIC)","Chinese Spondyloarthritis Inception Cohort","CESPIC","Inclusion Criteria:\n\nCrohn's disease. Acute anterior uveitis. Psoriatic arthritis with axial involvement. Reactive arthritis.\n\nExclusion Criteria:\n\nInfections, Malignancies, Major cardiovascular events, Lower intestinal perforations Other adverse events",{"count":57,"type":22},1000,"OBSERVATIONAL","The Chinese Spondyloarthritis Inception cohort (CESPIC) was started 2000 as a prospective, longitudinal, multicentre, nationwide study in China on patients with early SpA including ankylosing spondylitis (AS, also known as radiographic axial spondyloarthritis) and non-radiographic axial SpA. The objectives of CESPIC are to learn about the course of SpA during the very early stage of the disease, to appropriately assess the outcome including radiographic progression of patients after several years of follow-up, to identify outcome predictors, to assess quality of life, function, and costs (direct and indirect costs). CESPIC has been recently expanded to recruit patients with other forms of SpA \u002F conditions associated with SpA: reactive arthritis, acute anterior uveitis, Crohn's disease as well as with psoriasis \u002F axial psoriatic arthritis.",[30,61,62,63,64,65,66],"Non-radiographic Axial Spondyloarthritis (Nr-axSpA)","Axial Psoriatic Arthritis (axPsA)","Acute Anterior Uveitis (AAU)","Crohn Disease (CD)","Ulcerative Colitis (UC)","Reactive Arthritis (ReA)","2024-04-16",{"date":69,"type":39},"2024-04-17",{"date":71,"type":22},"2024-09",{"date":73,"type":22},"2030-08",{"name":75,"class":46},"Southwest Hospital, China",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":47},"100154069","german-spondyloarthritis-inception-cohort-100154069","NCT01277419","German Spondyloarthritis Inception Cohort","GESPIC","Main inclusion Criteria:\n\n* Patients with definite diagnosis of axial spondyloarthritis or juvenile spondyloarthritis.\n* Patients with definite diagnosis of Crohn's disease.\n* Patients with definite diagnosis of acute anterior uveitis.\n* Patients with definite diagnosis of psoriatic arthritis with axial involvement.",{"count":57,"type":22},"The German Spondyloarthritis Inception cohort (GESPIC) was started 2000 as a prospective, longitudinal, multicentre, nationwide study in Germany on patients with early SpA including ankylosing spondylitis (AS, also known as radiographic axial spondyloarthritis) and non-radiographic axial SpA. The objectives of GESPIC are to learn about the course of SpA during the very early stage of the disease, to appropriately assess the outcome including radiographic progression of patients after several years of follow-up, to identify outcome predictors, to assess quality of life, function, and costs (direct and indirect costs). GESPIC has been recently expanded to recruit patients with other forms of SpA \u002F conditions associated with SpA: acute anterior uveitis, Crohn's disease as well as with psoriasis \u002F axial psoriatic arthritis.",[30,61,62,63,64,65],"RECRUITING","2021-10-05",{"date":89,"type":39},"2021-10-12",{"date":91,"type":4},"2000-07",{"date":93,"type":22},"2030-07",{"name":95,"class":46},"Charite University, Berlin, Germany"]